The proposed bill aims to enhance access to 340B drugs by prohibiting manufacturers from restricting or interfering with the delivery of covered outpatient drugs to pharmacies that are under contract with 340B covered entities. The bill introduces new legal language under Minnesota Statutes, chapter 62J, specifically section 62J.96, which outlines that manufacturers cannot limit pharmacy access to these drugs unless such delivery is prohibited under the 340B Drug Pricing Program. Additionally, the bill provides definitions for key terms such as "manufacturer," "340B covered entity," and "covered outpatient drug," ensuring clarity in the application of the law.

Furthermore, the bill amends Minnesota Statutes 2023 Supplement, section 151.071, subdivision 2, to include a new ground for disciplinary action against manufacturers. Specifically, it adds a provision that violations of section 62J.96 by a manufacturer will be grounds for disciplinary action. This amendment aims to hold manufacturers accountable for any actions that may hinder pharmacy access to essential medications, thereby supporting the integrity of the 340B Drug Pricing Program and improving healthcare access for patients.